0000000000409135

AUTHOR

Anne-charlotte Laska

0000-0002-7330-940x

showing 2 related works from this author

Time for a Step Change? Improving the Efficiency, Relevance, Reliability, Validity and Transparency of Aphasia Rehabilitation Research through Core O…

2014

Considered and meticulous outcome measurement is central to rigorously conducted effectiveness trials, and in turn the relevance and reliability of the study findings to the patient, therapist or p...

Linguistics and Languagemedicine.medical_specialtyOutcome (game theory)Medical and Health SciencesLanguage and LinguisticsAphasia researchrehabilitation researchPhysical medicine and rehabilitationAphasiaDevelopmental and Educational PsychologymedicineRelevance (information retrieval)Reliability (statistics)Cochrane LibraryOutcome measuresLPN and LVNData scienceaphasiaData setCore (game theory)NeurologyOtorhinolaryngologyspeech therapyTransparency (graphic)Aphasia rehabilitationNeurology (clinical)Forum: Commentarymedicine.symptomcerebrovascular accidentClinical MedicinePsychology
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct